Posts for Ticker ‘KOOL’

Should You Chase Stem Cell Stocks? (ASTM, CYTX, GERN, NBS, OSIR, STEM, KOOL)

money-stack-image15We are seeing massive gap-ups this morning in stem cell stocks.  President Obama is signing an executive order which will lift the Bush ban on funding of embryonic stem cell funding.  What is interesting here is that this is not really new news other than the timing and the formality.  The following prices are as of 8:19 AM EST.

  • Aastrom Biosciences, Inc. (NASDAQ: ASTM) +87% at $0.62
  • Cytori Therapeutics, Inc. (NASDAQ: CYTX) +38% at $3.20
  • Geron Corporation (NASDAQ: GERN) +29% at $4.99
  • Neostem, Inc. (AMEX: NBS) NOT TRADED
  • Osiris Therapeutics, Inc. (NASDAQ: OSIR) NOT TRADED…. in pact with Genzyme, but for adult stem cells.
  • StemCells Inc. (NASDAQ: STEM) +55% at $2.15
  • Thermogenesis Corp. (NASDAQ: KOOL) +41% at $0.57

Many of these stem cell stocks will trade more on a “vote of confidence” rather than over what this means as far as “new news” is concerned.

JON C. OGG

Posted on: March 9, 2009 – 7:29 am in Biotech, Politics, , , , , , ,

The 52-Week Low Club (GNW)(UIS)(SRZ)(GGP)(KOOL)(DPTR)

Sad_clownGenworth  (GNW) DIvidend cut. Drops to $2.55 from 52-week high of $28.21.

Unisys (UIS) No news but falls over 30% to $.79 from 52-week high of $7.90.

Sunrise Assisted Living (SRZ) Large quarterly loss. Falls to $1.82 from 52-week high of $34.87.

General Growth (GGP) Analayst downgrade still hurting. Falls to $1.91 from 52-week high of $51.24.

THERMOGENESIS (KOOL) Product recall and quarterly loss. Falls to $.44 from 52-week high of $2.25.

Delta Petroleum (DPTR) Offer to buy company falls through. Stock off to $3.89 from 52-week high of $28.37.

Douglas A. McIntyre

Posted on: November 7, 2008 – 3:49 pm in HI/LOW, , , , , ,

Super Tuesday Election Winner: STEM CELLS (STEM, GERN, ASTM, IVGN, KOOL, NBS, OSIR)

Despite not knowing whom the ultimate winner of the 2008 Presidential election will be, it looks like stem cells may be one of the real bright spots as far as which area in biotech will be open for more funding down the road.  If the Democrats win this is a shoe in.  If McCain wins, the current research clamp-downs won’t likely be as stringent in 2009 and beyond as they are today.  If Romney stages a comeback, despite many thinking of him as a religious figure our indications are that he at worst would not be anywhere as tough on the stem cell studies as the current administration.  Public companies such as StemCells Inc. (NASDAQ: STEM), Geron Corporation (NASDAQ: GERN), Aastrom Biosciences, Inc. (NASDAQ: ASTM), and others are going to be watching closely.

If you look at Tradesports.com for the political futures, you can see the Presidential nominee futures right now if you want to make a determination where the actual money bets are going right now.  McCain is priced at $93.00 and Romney is now priced at $1.90, so this would indicate a 92.9% probability of a McCain nomination.  The Democrat race is much closer right now with Tradesports showing a Hillary Clinton nomination with a $54.60 price (down $8.40), and Obama with a $47.40 price (up $8.90).  So the futures are showing a McCain essentially as a shoe-in now, yet the Democrat race is still too close to call.  Guess what, this would be a win-win for stem cell research beyond this year.

Read More »

Posted on: February 6, 2008 – 9:33 am in Biotech, Politics, , , , , , , , , , , , , ,